If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Director Appointment

5 Apr 2016 10:11

RNS Number : 2028U
Cathay International Holdings Ld
05 April 2016
 

 

Cathay International Holdings Limited

("Cathay", the "Company")

 

Appointment of a Director

 

 

Hong Kong, 5 April 2016 - Cathay International Holdings Ltd. (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China, is pleased to announce the appointment of Dr. Chan Ching Har Eliza, JP, BBS, LL.D. (Hon), as an independent non-executive director of the Company on 29 March 2016.

 

Dr. Chan is a Senior Consultant of Zhong Lun Law Firm. She is a Member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), a Standing Member of the CPPCC Tianjin Committee, Foreign Economic Affairs Legal Counsel to the Tianjin Municipal People's Government, and an arbitrator of the China International Economic and Trade Arbitration Commission (CIETAC).

 

Dr. Chan serves as Chairman of Tseung Kwan O Hospital, Chairman of Pensions Appeal Panel, Member of the Administrative Appeals Board, Investigation Panel Member of the Hong Kong Institute of Certified Public Accountants and the Legal Advisor to The Hong Kong Chinese Enterprises Association. She is also the Chairman of the Hong Kong CPPCC (Provincial) Members Association Limited, Chairman of the Hong Kong CPPCC (Provincial) Members Foundation Limited, Honorary President of The Hong Kong China Chamber of Commerce and a Governor of The Canadian Chamber of Commerce in Hong Kong.

 

She was also formerly a Member of the Hong Kong Hospital Authority, Chairman of Kowloon Hospital, Chairman of Hong Kong Eye Hospital, Member of the Hong Kong Public Service Commission, Member of the Board of Education, Member of the Hong Kong Examination and Assessment Authority, Member of the Medical Council of Hong Kong, Member of Hospital Governing Committee of Queen Elizabeth Hospital, Council Member of The Hong Kong University of Science and Technology, Member of the Hong Kong Immigration Tribunal and Member of the Board of the Hong Kong Science and Technology Park Corporation.

 

Dr. Chan holds B.Sc (1979) from University of British Columbia, LL.B (1982) and LL.D (Hon)(2008) both from University of Victoria.

 

DETAILS OF PRESENT DIRECTORSHIPS

From

To

Company

Country of incorporation

Role

Oct 2009

Present

Tianjin International Holdings Limited

Hong Kong

Listed

Non-executive Director

 

March 2001

Present

Concord International Investment Ltd.

Hong Kong

Private

Director

June 1993

Present

Pacific Concord Holdings Ltd.

British Virgin Islands

Private

Director

Present

University of Victoria (Hong Kong) Foundation Limited

Hong Kong

Private

Director

About 2006

Present

Hong Kong CPPCC (Provincial) Members Association Ltd.

Hong Kong

Company limited by guarantee

Director

Present

Hong Kong CPPCC (Provincial) Members Foundation Ltd.

Hong Kong

Private

Director

DETAILS OF PAST DIRECTORSHIPS IN THE LAST 5 YEARS

26 March 2012

China Aerospace International Holdings Limited

Hong Kong

Listed

Non-executive director

July 1999

June 2015

Hong Kong Science & Technology Corporation

Hong Kong

Statutory body

Director

Dec 2015

Acudate Investments Ltd.

Hong Kong

Private

Director

 

-ENDS-

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Patrick Sung (Director and Controller)

Rebecca Yip (Company Secretary)

Tel: +852 2828 9289

 

N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell / Lauren Kettle - Corporate Finance

Brough Ransom - Sales

 

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

Tel: +44 (0) 20 3709 5702

 

About Cathay

 

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMGGDLKVGVZG
Date   Source Headline
30th Aug 201911:33 amRNSInterim Results
27th Aug 20194:10 pmRNSLansen reports interim results ended 30 June 2019
16th Aug 201911:46 amRNSNotice of Interim Results
1st Aug 20199:52 amRNSBlock listing Interim Review
25th Jul 201911:34 amRNSTrading Update
12th Jul 20199:24 amRNSChange of Registered Office Address in Bermuda
8th Jul 201912:32 pmRNSUpdate on cross guarantee agreement
28th Jun 20197:00 amRNSTotal Voting Rights
21st Jun 201911:56 amRNSUpdate re Natural Dailyhealth
21st Jun 201910:58 amRNSStatement relating to UK FCA enforcement action
20th Jun 201912:01 pmRNSUpdate on renewal of Cross Guarantee Agreement
12th Jun 201912:02 pmRNSChange of Company Secretary
12th Jun 201911:59 amRNSUpdate on renewal of Cross Guarantee Agreement
11th Jun 201911:41 amRNSDisposal of Starry Shares
10th Jun 20194:08 pmRNSResult of AGM
31st May 201910:51 amRNSStatement relating to UK FCA enforcement action
14th May 201911:54 amRNSDisposal of Starry Shares
3rd May 20192:24 pmRNSRenewal of Cross Guarantee
24th Apr 201912:23 pmRNSStarry Share Disposal
12th Apr 20199:42 amRNSResult of Special General Meeting
29th Mar 201912:49 pmRNSAnnual Results For the Year Ended 31 December 2018
27th Mar 20194:59 pmRNSProposed Further Disposal of Starry Shares
27th Mar 20198:01 amRNSLansen reports annual results
15th Mar 20197:00 amRNSNotice of Annual Results 2018
22nd Feb 20199:32 amRNSBlock listing Interim Review - Replacement
20th Feb 20193:24 pmRNSLansen's fourth share reduction plan of Starry
1st Feb 201910:52 amRNSBlock listing Interim Review
1st Feb 201910:45 amRNSTotal Voting Rights
25th Jan 20199:59 amRNSLansen's release of its Trading Update
31st Dec 20187:00 amRNSInvestment by Lansen in Robustnique
18th Dec 20188:02 amRNSTrading Update
30th Nov 20189:34 amRNSProposed Starry Shares Disposal by Lansen
12th Oct 201810:31 amRNSChange Of Director
20th Sep 20189:43 amRNSHolding(s) in Company
31st Aug 20189:47 amRNSInterim Results
28th Aug 20182:28 pmRNSLansen reports interim results
17th Aug 20187:00 amRNSNotice of Interim Results 2018
13th Jul 20189:11 amRNSTrading Update
4th Jul 20189:05 amRNSSecond Price Monitoring Extn
4th Jul 20189:00 amRNSPrice Monitoring Extension
25th Jun 20188:00 amRNSExtension of put option in Natural Dailyhealth
6th Jun 20181:25 pmRNSLansen's partial disposal of shares in Starry
5th Jun 20189:22 amRNSResults of Annual General Meeting
2nd May 201811:20 amRNSLansen subsidiary enters distribution agreement
16th Apr 201812:43 pmRNSLansen's shareholder loan to Natural Dailyhealth
9th Apr 201811:33 amRNSAnnual Results for the Year Ended 31 December 2018
3rd Apr 201810:14 amRNSLansen's third share reduction plan of Starry
27th Mar 20189:59 amRNS2017 Lansen Annual Results
15th Mar 20187:00 amRNSNotice of Results
9th Feb 20187:43 amRNSLansen appoints Executive Director & Group CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.